What do we mean by an “on-treatment” predictive biomarker for immunotherapy? Dirk Arnold MD, Ph.D., Executive Board Member of the European Society of Medical Oncology (ESMO) & Chief of Oncology at Asklepios Klinik Altona, recently…
Welcome to Oncolytics Insights. Here we will provide commentary on recent news, presentations and happenings related to Oncolytics and our development programs.
AACR 2019 Snapshot: A First Look at Predictive Biomarker Data from a Combination Study of Pelareorep + Keytruda® in Pancreatic Cancer
AACR 2019 was an important conference for us. We’ve been investigating the potential utility of a biomarker to help predict a patients response to receiving pelareorep combined with other immunotherapies, such as checkpoint inhibitors. This study is a first look at the utility of T cell clonality as a predictor of response to therapy, and we’re very excited about it.
During our presentation at the BIO CEO Investor conference, CEO Matt Coffey provided the backstory on the genesis of our AWARE-1 window of opportunity study and the intention to find a biomarker that would support a phase 3 registration study in metastatic breast cancer.